Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: https://orca.cardiff.ac.uk/id/eprint/132968/

This is the author’s version of a work that was submitted to / accepted for publication.

Citation for final published version:

Knight, Marian, Chiocchia, Virginia, Partlett, Christopher, Rivero-Arias, Oliver, Hua, Xinyang, Hinshaw, Kim, Tuffnell, Derek, Linsell, Louise, Juszczak, Edmund, Enderby, Helen, Thakar, Rane, Sultan, Abdul H., Sanders, Julia ORCID: https://orcid.org/0000-0001-5712-9989, Pasupathy, Dharmiltra, Moore, Philip, Gray, James and Khunda, Aethele 2019. Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. Lancet 393 (10189) , pp. 2395-2403. 10.1016/S0140-6736(19)30773-1 file

Publishers page: http://dx.doi.org/10.1016/S0140-6736(19)30773-1
<http://dx.doi.org/10.1016/S0140-6736(19)30773-1>

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial

Marian Knight, Virginia Chiocchia, Christopher Partlett, Oliver Rivera-Arias, Xinyang Hua, Kim Hinshaw, Derek Tuffnell, Louise Linsell, Edmund Juszczak, on behalf of the ANODE collaborative group

Summary

Background Risk factors for maternal infection are clearly recognised, including caesarean section and operative vaginal birth. Antibiotic prophylaxis at caesarean section is widely recommended because there is clear systematic review evidence that it reduces incidence of maternal infection. Current WHO guidelines do not recommend routine antibiotic prophylaxis for women undergoing operative vaginal birth because of insufficient evidence of effectiveness. We aimed to investigate whether antibiotic prophylaxis prevented maternal infection after operative vaginal birth.

Methods In a blinded, randomised controlled trial done at 27 UK obstetric units, women (aged ≥16 years) were allocated to receive a single dose of intravenous amoxicillin and clavulanic acid or placebo (saline) following operative vaginal birth at 36 weeks gestation or later. The primary outcome was confirmed or suspected maternal infection within 6 weeks of delivery defined by a new prescription of antibiotics for specific indications, confirmed systemic infection on culture, or endometritis. We did an intention-to-treat analysis. This trial is registered with ISRCTN, number 11166984, and is closed to accrual.

Findings Between March 13, 2016, and June 13, 2018, 3427 women were randomly assigned to treatment: 1719 to amoxicillin and clavulanic acid, and 1708 to placebo. Seven women withdrew, leaving 1715 in the amoxicillin and clavulanic acid group and 1705 in the placebo groups. Primary outcome data were missing for 195 (6%) women. Significantly fewer women allocated to amoxicillin and clavulanic acid had a confirmed or suspected infection (180 [11%] of 1619) than women allocated to placebo (306 [19%] of 1606; risk ratio 0·58, 95% CI 0·49–0·69; p<0·0001). One woman in the placebo group reported a skin rash and two women in the amoxicillin and clavulanic acid reported other allergic reactions, one of which was reported as a serious adverse event. Two other serious adverse events were reported, neither was considered causally related to the treatment.

Interpretation This trial shows benefit of a single dose of prophylactic antibiotic after operative vaginal birth and guidance from WHO and other national organisations should be changed to reflect this.

Funding NIHR Health Technology Assessment programme.

Introduction Sepsis causes 11% of maternal deaths globally;¹ in 2016, an estimated 19 500 women died because of pregnancy-related infections.² This burden is not limited to countries of low and middle income; 5% of maternal deaths in high-income settings are due to infection, and in the USA this figure has been estimated to be as high as 13%.³ For every woman that dies from pregnancy-related infection, 70 women have severe infection and survive, often with long-term health consequences.⁴ Maternal infection remains under-recognised and undertreated, and hence is the focus of a WHO global study and awareness campaign.⁵

Risk factors for maternal sepsis can be easily recognised, including caesarean section and operative vaginal birth (forceps or vacuum extraction).⁶ Without prophylaxis, an estimated 20–25% of women have an infection following caesarean birth,⁷ and up to 16% have an infection following operative vaginal birth.⁸ There is strong evidence from a systematic review⁹ in women giving birth by caesarean section, that the use of prophylactic antibiotics reduces the incidence of wound infection, endometritis, and serious maternal infection by 60–70%. Antibiotic prophylaxis at caesarean section is therefore widely recommended.¹⁰ Another systematic review¹¹ identified only one small, low-quality evidence trial of antibiotic prophylaxis in operative vaginal birth, reporting only two outcomes, endometritis and maternal length of hospital stay, with no difference between women receiving an antibiotic and those receiving placebo.¹² Recognising the importance of antibiotic stewardship where evidence of benefit is insufficient, current guidelines explicitly state that routine antibiotic prophylaxis is not recommended for women undergoing operative vaginal birth.¹³¹⁴

Although numbers of caesarean births are increasing worldwide,¹⁵ and in many countries the proportion
Articles

Research in context

Evidence before this study
We searched PubMed on Dec 7, 2018, for all studies about operative vaginal birth and antibiotic prophylaxis, using the search terms “forceps”, “ventouse”, “vacuum extraction”, “antibiotic”, “prophylaxis”, “infection”, and “sepsis”. Published since Jan 1, 1980, with no language restrictions. All modes of operative birth, caesarean section and operative vaginal (forceps and vacuum-assisted) births are known to be associated with post-partum infection. The proportion of women who develop an infection without antibiotic prophylaxis is estimated to be 20–25% after a caesarean birth and up to 16% after an operative vaginal birth. A Cochrane systematic review, updated in 2014, identified 95 trials of antibiotic prophylaxis in women giving birth by caesarean section, and showed that the use of prophylactic antibiotics reduced the incidence of wound infection, endometritis, and serious maternal infection by 60–70%. By contrast, a Cochrane review of antibiotic prophylaxis in operative vaginal birth, updated in 2017, identified only one small, low-quality evidence trial, of 393 women reporting only two outcomes: endometritis and maternal length of hospital stay. There was no evidence of a difference in infections between women receiving an antibiotic and those receiving placebo. Recognising the importance of antibiotic stewardship where evidence of benefit is lacking, current WHO and national guidelines therefore explicitly state that routine antibiotic prophylaxis is not recommended for women undergoing operative vaginal birth.

Added value of this study
This large multicentre trial was adequately powered to robustly examine the effect of antibiotic prophylaxis following operative vaginal birth. It showed a clear reduction in the proportion of women who had a confirmed or suspected infection after operative vaginal birth in the intervention group, as well as lower proportions of women with perineal wound infection, perineal pain, or perineal wound breakdown after antibiotic prophylaxis, which, to the best of our knowledge, has not previously been shown.

Implications of all the available evidence
Antibiotic prophylaxis is effective in preventing up to a half of confirmed or suspected maternal infections during the 6 weeks after operative vaginal birth. These findings suggest that current guidance should be updated to reflect the benefit of routine antibiotic prophylaxis after operative vaginal birth in clinical practice.

Methods

Trial design and oversight
The ANODE trial was a multicentre, randomised, blinded, controlled trial done at 27 hospital obstetric units in the UK. The trial protocol has been published previously and the full protocol is available in the appendix. Women who had undergone forceps or vacuum delivery at 36 weeks or greater gestation, with no indication for ongoing prescription of antibiotics in the post-partum period and no contraindications to prophylactic amoxicillin and clavulanic acid, were randomly assigned (1:1) to receive a single intravenous dose of prophylactic amoxicillin and clavulanic acid or placebo. This trial was approved by the Health Research Authority National Research Ethics Service Committee South Central—Hampshire B (study ref: 15/SC/0442).

The trial statisticians did the analysis, prepared the closed reports and attended the closed session of the data monitoring committee meetings. The trial statisticians and the data monitoring committee were masked to trial allocation until the database was locked for the final analysis. No other parties had access to the data presented at the closed data monitoring committee meeting. A 9-month internal pilot was done and evaluated by the trial steering committee according to the guidelines in the appendix.

Participants
Women were eligible for inclusion if they were age 16 years or older, willing and able to give informed consent, and had undergone operative vaginal birth at 36 weeks or greater gestation. Women undergoing all types of operative vaginal birth were eligible for inclusion, irrespective of the instrument used, whether rotation was undertaken, or the station of the fetal head at the time of instrument application. They were ineligible if they had any clinical indication for antibiotic administration after delivery, including, but not limited to, confirmed antenatal or intrapartum infection, or third-degree or fourth-degree perineal tears (obstetric anal sphincter injury). Receipt of antenatal or intrapartum antibiotics, such as for prolonged rupture of membranes, was not a reason for exclusion if women had no indication for ongoing antibiotic treatment.
prescription after delivery. Women who had a known allergy to penicillin or any of the components of amoxicillin and clavulanic acid, or who had a history of anaphylaxis to another β-lactam agent were also excluded.

Women gave written consent to participate, unless there were time or other constraints, in which case they gave verbal consent followed by full written consent before hospital discharge for inclusion of their data in the trial and for participation in the planned follow-up.

Randomisation and masking
A randomisation list was generated by use of permuted blocks of variable size to ensure balance and unpredictability overall. Pack numbers were added to the randomisation list by an independent trials programmer who liaised directly with the packaging and distribution company. Centres were supplied with sealed, sequentially numbered, indistinguishable packs containing active drug or placebo as designated. Women were randomly assigned (1:1) by the allocation of the next sequentially numbered pack once consent and eligibility were established. The implementation of the allocations was monitored by assessment of whether packs were allocated sequentially as per protocol.

Women, most clinicians (including research midwives and those taking consent), and midwives, nurses, or doctors collecting outcome information were masked to allocation. Clinical staff responsible for preparing and checking the trial drug were not masked to allocation but they had no other role in the trial.

Procedures
Women in the intervention group received a single dose of intravenous amoxicillin and clavulanic acid (1 g amoxicillin and 200 mg clavulanic acid) as soon as possible and no more than 6 h after giving birth. Women in the placebo group received 20 mL of intravenous sterile 0·9% saline within the same timeframe. The intervention was administered after the women had given birth because of concerns about the effects of prenatal exposure to antibiotics on the infant microbiome. Unlike other surgical sites, the perineal wound cannot be covered, therefore post-delivery administration of antibiotic increased the length of time that there was a therapeutic level of antibiotic from a single dose, to cover for ongoing contamination for as long as possible.

Outcome information, including information on antibiotic prescription for presumed infection, was collected from medical records at hospital discharge and by a telephone interview at 6 weeks post delivery, after which women were sent a questionnaire for collection of data on secondary outcomes. If women responded to the questionnaire, but not the telephone interview, two investigators masked to allocation independently reviewed their questionnaire responses for any evidence that they had the primary outcome. Clinical data on outcomes, including antibiotic prescription, were collected from medical records or the hospital laboratory at initial discharge and at 6 weeks post delivery, if women indicated they had a possible infection, antibiotic prescription for presumed infection, or attended hospital, or if women did not respond to the telephone interview or questionnaire.

All trial data were entered into electronic case report forms in an OpenClinica database in which participants were identified only by a trial specific number. Women’s names and other identifying details were stored in a separate bespoke database linked only by the trial number.

Outcomes
The primary outcome was confirmed or suspected maternal infection within 6 weeks of delivery, as defined by a new prescription of antibiotics for presumed perineal wound-related infection, endometritis or uterine infection, urinary tract infection with systemic features (pyelonephritis or sepsis) or other systemic infection (clinical sepsis); confirmed systemic infection on culture; or endometritis, as defined by the US Centers for Disease Control and Prevention. An episode of endometritis required at least one of the following criteria to be met: organisms were cultured from fluid (including amniotic fluid) or tissue from endometrium obtained during an invasive procedure or biopsy, or the woman exhibited at least two of fever (>38°C), abdominal pain, uterine tenderness, or purulent drainage from uterus (with no other recognised cause for the latter three symptoms). The primary outcome was modified during the course of the trial at the request of the data monitoring committee to include only antibiotic prescription for the specific indications listed, instead of antibiotic prescription for any indication, to ensure that the primary outcome only included antibiotic prescriptions for infections potentially preventable by the trial intervention. This protocol amendment was made on Nov 30, 2017.

Secondary outcomes examined were systemic sepsis defined according to modified systemic inflammatory response syndrome criteria for pregnancy, perineal wound infection defined according to the Public Health England surveillance definition of surgical site infection, perineal pain, use of pain relief, hospital bed stay until discharge, need for additional perineal care, dyspareunia, ability to sit comfortably to feed the baby, maternal health-related quality of life, breastfeeding, wound breakdown, intervention side-effects, health-care resource use and costs.

The safety reporting window for this trial was from administration of intervention to 6 h post administration or discharge—whichever was sooner. Non-serious adverse events were not routinely recorded because the intervention is a licensed product being given at a standard dose; however adverse events that were part of the study outcomes were recorded in the data collection forms.
3427 enrolled and randomly assigned to treatment

1719 allocated to amoxicillin and clavulanic acid

4 withdrew consent

1715 included at baseline

37 did not receive treatment

19 cannula issues

4 unwell or declined

2 staff misunderstandings

4 were >6 h since delivery

2 withdrew

6 clinical reasons

1668 received placebo

1705 included in intention-to-treat analysis

37 did not receive placebo

25 cannula issues

3 unwell or declined

4 staff misunderstandings

1 was >6 h since delivery

2 withdrew

2 clinical reasons

1678 received treatment

1708 allocated to placebo

3 withdrew consent

1705 included at baseline

1708 included in intention-to-treat analysis

Figure: Trial profile

Formal screening logs were not kept, so numbers of participants screened and excluded before enrolment are not available.

All serious adverse events were reported immediately, at least within 24 h; except birth defect or congenital anomaly, hypertensive disorder of pregnancy (eg, pre-eclampsia or eclampsia), or post-partum haemorrhage with onset before the intervention, which were not considered to be causally related to the trial intervention because the events occurred before the trial intervention was administered.

Statistical analysis

The systematic review of antibiotic prophylaxis for operative vaginal birth suggested a conservative estimate of infection post birth of 4%. We anticipated an estimated relative risk reduction of 50% in this percentage with antibiotics on the basis of the reduction observed in the antibiotic prophylaxis for caesarean section trials. To detect such a difference with 90% statistical power at the two-sided 5% level of significance required 1626 women per group. To account for an estimated 5% loss to follow-up, we aimed to recruit 1712 women per group, a total of 3424 women, to the trial.

Women were analysed in the groups into which they were randomly allocated, regardless of intervention received (full analysis dataset; intention-to-treat [ITT] population). Analysis was done according to a prespecified, approved statistical analysis plan (appendix). Women were described with respect to their demographic and clinical characteristics at trial entry. Characteristics of women with incomplete primary outcome data were also described alongside those with complete primary outcome data. Descriptive analyses used n (%) for binary and categorical variables, and mean (SD) or median (IQR, and minimum and maximum values if appropriate) if the data were skewed for continuous variables.

Comparative analyses of binary outcomes used Poisson regression with robust standard errors, and results are presented as unadjusted risk ratios (RR) with associated CI. 95% CIs are presented for analyses of the primary outcome and more stringent 99% CIs are presented for secondary outcomes. No other adjustment was made for multiple testing. Maternal quality of life, assessed by use of EQ-5D-5L scores estimated with the most up-to-date preference-based value set, were summarised in each group using mean (SD) and compared between groups using mean differences (99% CI). Hospital bed stay until discharge was summarised as the median (IQR) in each group, and compared using the difference in medians (99% CI) and the Wilcoxon rank-sum test.

Four sensitivity analyses were done examining the primary outcome: restricted to women who had not received antibiotics in the 7 days before delivery, to examine whether any masking of a prophylactic effect was occurring by inclusion of pretreated women; excluding women prescribed antibiotics (other than the trial intervention) within the first 24 h after delivery, and who might therefore already have had an infection at the time of administration of the intervention; restricted to women whose primary outcome was obtained between weeks 6 and 10 after delivery to exclude any biases by over-reporting of outcomes from data returned at a later timepoint or under-reporting of outcomes in data returned at an earlier timepoint; and including centre as a random effect. No subgroup analyses were planned; however, we did a post-hoc subgroup analysis of the primary outcome according to mode of birth (forceps or vacuum extraction). More stringent 99% CIs are presented for the estimate of RR for this post-hoc subgroup analysis.

As a further analysis, not included in the original trial protocol, we did a within-trial comparison of health-care resource use and associated costs among women who completed the 6-week post-delivery questionnaire. The perspective of the analysis was that of the UK National Health Service (NHS) and the following categories of resource use were considered: antibiotic use (intervention and new prescriptions), health-care professional visits, outpatient hospital visits, and all-cause hospital readmissions. Sources and associated estimates of unit costs (expressed in 2017/18 GBP) are presented in the appendix. Costs associated to each category of resource use were estimated by multiplying resource use by unit costs. We did a complete case analysis and present mean (SD) of the number of visits or number of days (for readmissions) for each category of resource use and trial group. We also present overall mean (SD) costs at 6 weeks.
following delivery adding all individual cost categories. Mean differences in resource use and overall costs were calculated and associated 99% parametric CI estimated. All analyses were done using Stata, version 15.

The trial was overseen by an independent trial steering committee and safety was monitored by an independent data monitoring committee. The data monitoring committee reviewed interim efficacy and safety data at least annually, or more often if appropriate, and advised on the conduct of the trial to the trial steering committee.

This trial is registered with ISRCTN, number 11166984, and is closed to accrual.

**Role of the funding source**

ANODE was funded by the National Institute for Health Research HTA Programme (project number 13/96/07). The funder had no role in study design, data collection, data analysis, data interpretation or writing of the report. Authors MK, VC, OR-A, XH, LL, and EJ had full access to all the data in the study and MK had final responsibility for the decision to submit for publication.

**Results**

Between March 13, 2016, and June 13, 2018, 3427 women were randomly assigned to treatment: 1719 to amoxicillin and clavulanic acid and 1708 to placebo. Seven women withdrew after allocation; thus, 3420 were included in an independent data monitoring committee. The data monitoring committee reviewed interim efficacy and safety data at least annually, or more often if appropriate, and advised on the conduct of the trial to the trial steering committee.

This trial is registered with ISRCTN, number 11166984, and is closed to accrual.

### Table 1: Baseline characteristics (intention-to-treat population)

<table>
<thead>
<tr>
<th></th>
<th>Amoxicillin and clavulanic acid (n=1715)</th>
<th>Placebo (n=1705)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age, years</td>
<td>30.3 (5.37)</td>
<td>30.2 (5.49)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Gestational age at randomisation, weeks</td>
<td>40 (39–41)</td>
<td>40 (39–41)</td>
</tr>
<tr>
<td>36 to &lt;38</td>
<td>136 (8%)</td>
<td>123 (7%)</td>
</tr>
<tr>
<td>38 to &lt;40</td>
<td>568 (33%)</td>
<td>555 (33%)</td>
</tr>
<tr>
<td>40 to &lt;42</td>
<td>964 (56%)</td>
<td>968 (57%)</td>
</tr>
<tr>
<td>≥42</td>
<td>46 (3%)</td>
<td>59 (3%)</td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>1436 (84%)</td>
<td>1474 (87%)</td>
</tr>
<tr>
<td>Indian</td>
<td>36 (2%)</td>
<td>34 (2%)</td>
</tr>
<tr>
<td>Pakistani</td>
<td>73 (4%)</td>
<td>54 (3%)</td>
</tr>
<tr>
<td>Bangladeshi</td>
<td>8 (&lt;1%)</td>
<td>14 (1%)</td>
</tr>
<tr>
<td>Black Caribbean</td>
<td>6 (&lt;1%)</td>
<td>8 (&lt;1%)</td>
</tr>
<tr>
<td>Black African</td>
<td>32 (2%)</td>
<td>29 (2%)</td>
</tr>
<tr>
<td>Other</td>
<td>116 (7%)</td>
<td>85 (5%)</td>
</tr>
<tr>
<td>Missing</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Body-mass index at booking, kg/m²</td>
<td>25 (22–28)</td>
<td>25 (22–29)</td>
</tr>
<tr>
<td>&lt;18.5</td>
<td>46 (3%)</td>
<td>48 (3%)</td>
</tr>
<tr>
<td>18.5–24.9</td>
<td>851 (51%)</td>
<td>842 (51%)</td>
</tr>
<tr>
<td>25–29.9</td>
<td>460 (28%)</td>
<td>446 (27%)</td>
</tr>
<tr>
<td>30–34.9</td>
<td>207 (12%)</td>
<td>216 (13%)</td>
</tr>
<tr>
<td>35–39.9</td>
<td>74 (4%)</td>
<td>77 (5%)</td>
</tr>
<tr>
<td>≥40</td>
<td>32 (2%)</td>
<td>34 (2%)</td>
</tr>
<tr>
<td>Missing</td>
<td>45</td>
<td>42</td>
</tr>
<tr>
<td>Twin pregnancy</td>
<td>11 (1%)</td>
<td>9 (1%)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Any previous pregnancies ≥22 weeks gestation</td>
<td>402 (23%)</td>
<td>373 (22%)</td>
</tr>
<tr>
<td>Missing</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Previous caesarean section</td>
<td>137 (8%)</td>
<td>123 (7%)</td>
</tr>
<tr>
<td>Missing</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Previous episiotomy</td>
<td>147 (9%)</td>
<td>141 (8%)</td>
</tr>
<tr>
<td>Missing</td>
<td>26</td>
<td>25</td>
</tr>
<tr>
<td>Previous tear</td>
<td>81 (5%)</td>
<td>80 (5%)</td>
</tr>
<tr>
<td>Missing</td>
<td>24</td>
<td>26</td>
</tr>
<tr>
<td>Rupture of membranes before delivery, h</td>
<td>1692 (99%)</td>
<td>1683 (99%)</td>
</tr>
<tr>
<td>&lt;24</td>
<td>1461 (85%)</td>
<td>1466 (86%)</td>
</tr>
<tr>
<td>≥24 to &lt;48</td>
<td>191 (11%)</td>
<td>175 (10%)</td>
</tr>
<tr>
<td>≥48</td>
<td>35 (2%)</td>
<td>36 (2%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>5 (&lt;1%)</td>
<td>6 (&lt;1%)</td>
</tr>
<tr>
<td>Missing</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

(Table 1 continues in next column)
the primary ITT analysis, 1715 in the amoxicillin and clavulanic acid group and 1705 in the placebo group (figure). The baseline characteristics of the two groups were similar (table 1). 2641 (77%) women were primiparous and 1671 (49%) had induction of labour. 437 (13%) women had ruptured membranes for more than 24 h before they gave birth. 2234 (65%) births were by forceps and 1196 (35%) were by vacuum extraction. The majority of women (3044, 89%) had an episiotomy. Primary outcome data were available for 195 (6%) women; the characteristics of these women were not significantly different from women for whom primary outcome data were available (appendix).

74 (2%) women (37 in each group) did not receive their allocated intervention, 44 (59%) because of cannula issues (figure). Women allocated to the intervention group received amoxicillin and clavulanic acid a median of 3·2 h (IQR 2·2–4·5) after they gave birth; 19 (1%) women received the antibiotic more than 6 h after giving birth. Women allocated to the placebo group received saline a median of 3·1 h (IQR 2·1–4·4) after they gave birth; 14 (1%) women received the placebo more than 6 h after giving birth.

The proportion of women who had overall primary outcome events was higher than anticipated (486 [15%] of 3225). A significantly smaller number of women allocated to the amoxicillin and clavulanic acid group had a confirmed or suspected infection (180 [11%] of 1619) than women who were allocated to the placebo group (306 [19%] of 1606; RR 0·58, 95% CI 0·49–0·69; p<0·0001; table 2). The primary outcome was dominated by a new prescription of antibiotics for presumed perineal wound-related infection, endometritis or uterine infection, urinary tract infection with systemic features, or other systemic infection; however, the proportion with confirmed systemic infection on culture was also significantly reduced in the amoxicillin and clavulanic acid group compared with the placebo group (0·6% vs 1·5%, respectively; RR 0·44, 95% CI 0·22–0·89; p=0·018).

At 6-weeks post delivery, the proportions of women with perineal infection (table 2), perineal pain, use of pain relief for perineal pain, need for additional perineal care and wound breakdown (table 3), were significantly lower among women allocated to the amoxicillin and clavulanic acid group compared with the placebo group. Women allocated to the amoxicillin and clavulanic acid group were also significantly less likely to report that their perineum was ever too uncomfortable to feed their baby, or to report any primary care physician or home visits or any hospital outpatient visits in relation to concerns about their perineum compared with those allocated placebo (table 3). The incidence of systemic sepsis defined according to modified systemic inflammatory response syndrome criteria for pregnancy (table 2), the proportion of women who were breastfeeding, the proportion of women who had dyspareunia, length of hospital stay to discharge or number of hospital readmissions, or overall maternal quality of life were not different between the two groups (table 3).

Side-effects of the trial intervention were reported by three women. One woman in the placebo group reported a skin rash and two women in the amoxicillin and clavulanic acid group reported other allergic reactions. One of these allergic reactions was reported as a serious adverse event. Two other serious adverse events were reported, neither was considered causally related to the trial intervention. No women had an anaphylactic reaction.

Results of all sensitivity analyses were not different to those of the main analysis (appendix). The estimate of effect in the post-hoc analysis of the primary outcome according to mode of operative birth was not significantly different between the subgroups (p=0·727; appendix).

At 6 weeks post-delivery, women allocated to receive amoxicillin and clavulanic acid used fewer NHS healthcare resources compared with women allocated to receive placebo (appendix). The mean difference in all categories of resource use favoured the amoxicillin and clavulanic acid group, with significant mean differences in visits to the general practitioner (mean difference −0·11 visits, 95% CI −0·17 to −0·04), nurse or midwife home visits (−0·18 visits, −0·30 to −0·06), and outpatient hospital visits (−0·14 visits, −0·24 to −0·04). No significant mean
differences were detected in the length of stay for all cause hospital readmissions. The total mean costs at 6 weeks following delivery was estimated to be £102·50 (SD £652·40) in the amoxicillin and clavulanic acid group and £155·10 (£497·40) in the placebo group—a mean difference of –£52·60 (99% CI –£115·10 to £9·90).

Discussion

The ANODE trial therefore provides evidence of benefit of prophylactic antibiotic administration after operative vaginal birth, with few observed adverse events in relation to the intervention, indicating an urgent need to change current clinical practice to prevent maternal morbidity. Our post-hoc subgroup analysis (appendix) showed that an almost halving of the number of women with an infection was seen both among women who had a forceps birth and women who had vacuum-assisted births, although the proportion of women with confirmed or suspected infection was lower among women who had vacuum-assisted births. The additional resource use analysis (appendix) done for the ANODE trial estimates that for each additional 100 doses of antibiotic used in prophylaxis, 168 treatment doses will be saved, representing a 17% overall reduction in antibiotic use with a policy of universal prophylaxis.

WHO guidelines for the prevention of maternal infection,9 and national professional organisational guidelines on operative vaginal delivery in the UK, North America, and Australasia currently do not recommend antibiotic prophylaxis after instrumental vaginal birth.12–14 The proportions of women who have operative vaginal birth

| Table 3: Secondary outcomes at 6 weeks post-delivery based on data from questionnaire (intention-to-treat population) |
|---------------------------------------------------|------------------|-----------------|-----------------|-----------------|
| Perineal pain                                      | 592 (46%)        | 707 (55%)       | 0.84 (0.76 to 0.93)* | <0.0001          |
| Missing                                           | 0                | 0               | NA               | NA               |
| Use of pain relief for perineal pain              | 99 (8%)          | 128 (11%)       | 0.72 (0.52 to 0.99)* | 0.0073           |
| Missing                                           | 13               | 18              | NA               | NA               |
| Need for additional perineal care                 | 390 (31%)        | 543 (43%)       | 0.72 (0.61 to 0.83)* | <0.0001          |
| Missing                                           | 42               | 38              | NA               | NA               |
| Wound breakdown                                   | 142 (11%)        | 272 (21%)       | 0.52 (0.41 to 0.67)* | <0.0001          |
| Missing                                           | 4                | 7               | NA               | NA               |
| Dyspareunia†                                      | 299 (55%)        | 280 (54%)       | 1.01 (0.87 to 1.17)* | 0.873            |
| Missing                                           | 5                | 8               | NA               | NA               |
| Breastfeeding at 6 weeks                          | 662 (51%)        | 657 (51%)       | 1.01 (0.91 to 1.11)* | 0.828            |
| Missing                                           | 4                | 4               | NA               | NA               |
| Perineum ever too painful or uncomfortable to feed baby | 136 (11%)        | 198 (12%)       | 0.69 (0.53 to 0.90)* | <0.00025         |
| Missing                                           | 96               | 98              | NA               | NA               |
| Hospital bed stay to discharge                    | 1 (1-2)          | 1 (1-2)         | 0.0 (0 to 0)     | 0.318            |
| Missing                                           | 0                | 0               | NA               | NA               |
| Any primary care or home visits in relation to perineum | 361 (28%)        | 496 (38%)       | 0.73 (0.61 to 0.84)* | <0.0001          |
| Missing                                           | 3                | 5               | NA               | NA               |
| Any outpatient visits in relation to perineum     | 95 (7%)          | 173 (13%)       | 0.55 (0.40 to 0.75)* | <0.0001          |
| Missing                                           | 5                | 6               | NA               | NA               |
| Maternal hospital re-admission                    | 63 (5%)          | 84 (7%)         | 0.75 (0.49 to 1.14)* | 0.072            |
| Missing                                           | 47               | 51              | NA               | NA               |
| Maternal health-related quality of life           | EQ-5D-5L score   | 0·935 (0·098)   | 0·927 (0·111)    | 0·008 (0·003 to 0·019)§ | 0·048       |
| Missing                                           | 16               | 18              | NA               | NA               |

Data are n (%), n, median (IQR), or mean (SD). NA=not applicable. EQ-5D-5L=five-level EuroQol-5D questionnaire. *Risk ratio (risk in amoxicillin and clavulanic acid group/risk in placebo group). †Denominator is all women who have attempted intercourse since giving birth (n=544 amoxicillin and clavulanic acid group, n=514 control group). ‡Difference in medians for hospital bed stay to discharge. §Difference in means.
Articles

...are variable; 12% of women have instrumental vaginal
birth in the UK,5,6 in the USA the figure is closer to 3–4%,7,8 and it is estimated to be less than 1% in some low-income
settings.9 From our results, a high proportion of women—at
least one in five—experience an infective complication
and this can be reduced by almost half. This equates to
prevention of more than 7000 infections annually in the
UK with associated perineal complications, and around
5000 per year in the USA with routine use of antibiotic
prophylaxis at operative vaginal delivery.

In this trial, we defined suspected or confirmed maternal
infection using a composite outcome, including a new
prescription of antibiotics for confirmed or suspected
infection, which can be interpreted as equating to a clinical
diagnosis of infection. This clinical diagnosis of infection
drove the overall outcome and resulted in a substantially
higher than anticipated percentage of events albeit with an
effect size in keeping with our previous assumption,
reflecting the high rate of perineal wound infection, which
was not measured in the previous trial, and on which we
based our anticipated event number. The use of this
clinical definition, rather than microbiologically confirmed
infection, could be regarded as a limitation; however, we
observed a significant decrease in the percentage of micro-
bio logically confirmed systemic infection following culture
from a sterile site, which supports the assumption that the
findings represent a true decrease in infection, despite
our pragmatic primary outcome definition. Our primary
outcome definition enhances the generalisability of our
findings to low-income and middle-income settings in
which microbiological confirmation of infection is difficult
or impossible, with a clinical diagnosis of infection the
only possible proxy.

We achieved a follow-up of only 76% for the majority of
our secondary outcomes, which represents the main
limitation of this trial. A greater proportion of women
who returned the 6-week questionnaire were primiparous.
Their consultation behaviour might have differed from
multiparous women, and thus the percentages of some of
the reported secondary outcomes might be higher than
would be seen in the general population. However, this
difference in characteristics between women with
and without follow-up data is unlikely to account for
the magnitude of difference we observed between the
amoxicillin and clavulanic acid group and the placebo
group.

We asked sites to administer the intervention as soon as
possible, and no later than 6 h, after women had given
birth; in practice, it was administered a median of 3 h after
women had given birth. It is possible that administration
this length of time after women had given birth made
the amoxicillin and clavulanic acid less effective than it
might have been earlier, given that caesarean section trials
suggest that predelivery administration is more effective
at preventing wound infection and endometritis. However,
the perineal wound, which is highly likely to become
contaminated, is different from the caesarean section
wound, and later administration might have allowed for a
longer duration of protective effect and greater efficacy.
Further analyses are needed to investigate the mechanism
of effect.

This study shows a high proportion of complications
after operative vaginal delivery, not illustrated as clearly in
other studies, which generally report proportions of
infection lower than 10%. Many observational studies of
infections after operative vaginal birth only followed up
women until hospital discharge.8 The majority of
complications we observed occurred after discharge and
follow-up to 6 weeks might be regarded as a strength of
this trial. Even in the antibiotic group, more than one in
every ten women had a postnatal infective complication,
which emphasises the importance of ongoing awareness
of potential infection and further research to identify ways
to reduce this proportion further. Almost half of women
reported ongoing perineal pain 6 weeks after giving birth
and 11% had a breakdown of their perineal wound. It is
unclear whether these effects will continue long term,
ethough other studies have reported ongoing problems
in women 6–9 months after a dehisced perineal wound.26

This trial was limited to women who were not allergic to
penicillin, and used a single antibiotic. However, the
results are likely to be comparable if antibiotics with
a similar spectrum of activity are used and would therefore
be generalisable to women who are allergic to penicillin.

This trial was done in a high-income setting, but given the
pragmatic nature of the trial and the simple intervention,
the findings are likely to be generalisable to low-income
and middle-income settings in which intravenous
antibiotics are available. It is unclear whether prophylactic
antibiotics administered orally would have the same
preventive efficacy and this would need further research.
The antibiotic was effective when administered a median
of 3 h after delivery, but nevertheless 11% of women who
received the antibiotic had a confirmed or suspected
infection. Further analysis of the mechanism of action of
this single dose of antibiotic is needed to investigate
whether earlier administration, prenatal administration,
or repeated administration is likely to be more effective
than the single intravenous dose administered 3 h after
women gave birth. Until these analyses are completed,
there is no indication for administration of more than a
single dose of prophylactic antibiotic, or for predelivery
administration. In conclusion, this trial shows clear benefit
of a single dose of prophylactic antibiotic after operative
vaginal birth, and guidance should be changed to reflect
this finding.

Contributors
MK wrote the first draft of the Article with contributions from VC, OR-A,
and XH. CP, VC, LL, and EJ developed the analysis plan. CP, VC, LL, EJ,
OR-A, and XH did the analyses. All authors formed the fast-track writing
group and edited and approved the final version of the Article.
All authors and all members of the ANODE collaborative group
(including HE, JG, AK, PM, DP, AHS, JS, and RT) contributed to the
development and conduct of the trial, and the writing and editing of the
final trial report.
ANODE collaborative group
Marjan Knight, Helen Enderby, Derek Tuffnell, Kim Hinshaw, Ranee Thakar, Abdul H Sultan, Julia Sanders, Dharmintra Pasupathy, Philip Moore, James Gray, Oliver Rivero-Arias, Ed Juszczak, Louise Linsell, Athele Khunda

Declaration of interests
MK, OR, A. L., and EJ report receipt of funding from NIHR, outside the submitted work. All other authors have no competing interests to declare. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Data sharing
De-identified participant data will be shared in accordance with the National Perinatal Epidemiology Unit Data Sharing policy. Requests for access to the data will be considered by the National Perinatal Epidemiology Unit Data Sharing committee from the date of publication. Data will be shared after approval of a proposal with investigator approval and completion of a signed data sharing agreement. The trial protocol, statistical analysis plan, and other study documents are also available on request through this route. Access to the data can be requested from general@npeu.ox.ac.uk.

Acknowledgments
We acknowledge the independent members of the data monitoring and trial steering committees (appendix).

References